Market Overview

Credit Suisse Reports Ariad's Iclusig is 'Essential Drug'

Related ARIA
JMP Securities Downgrades Ariad, Cites Limited Near-Term Upside In Light Of Prescription Trends
The Market In 5 Minutes: UA, GM, P&G Earnings On The Street's Mind
Ariad Pharmaceuticals: How The Lawmakers Will Get This Wrong (Seeking Alpha)

In a report published Friday, Credit Suisse analyst Jason Kantor maintained a Neutral rating on Ariad Pharmaceuticals (NASDAQ: ARIA) and raised the price target from $5.00 to $8.00 on higher Iclusig estimates and possible acquisition.

Kantor noted that a survey from 50 doctors suggests that Ariad's Iclusig remains the “essential drug” for chronic myeloid leukemia patients with T3151 or other mutations. The analyst commented that doctors have a heightened awareness of safety concerns. Credit Suisse added that 38% of doctors sampled report observing at least one adverse event listed in warnings in Iclusig prescribing information.

Ariad Pharmaceuticals closed at $7.17 on Thursday. Shares were up 5.6% in pre-market trading and have traded as high as $8.29, up 15.62% on Friday.

Latest Ratings for ARIA

Oct 2016JMP SecuritiesDowngradesMarket OutperformMarket Perform
Oct 2016JP MorganDowngradesNeutralUnderweight
Oct 2016SunTrust Robinson HumphreyInitiates Coverage onBuy

View More Analyst Ratings for ARIA
View the Latest Analyst Ratings

Posted-In: Credit Suisse Jason KantorAnalyst Color Price Target Analyst Ratings


Related Articles (ARIA)

View Comments and Join the Discussion!